Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

GSK Lotronex Indication Suggests Potential Market Of $280 Mil.

Jun 17 2002

• By The Pink Sheet

Related Content

GSK Lotronex Risk Management Program Allows For Off-Label Use

Jun 17 2002

GSK Lotronex Plan Follows Accutane Model; Relaunch “Months” Away

Jun 10 2002

Glaxo Lotronex Indication Would Cover One-Third Of IBS Patients

Nov 22 1999

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window